Celyad Sa Stock Predictions

Healthcare > Biotechnology

Buy CYAD

*Your capital is at risk

$0.470

+0 (+0%)

At Close: Aug 17, 2023

Currently predicting for Fri, 5 Jun 2026

CYAD Prediction Chart

CYAD Predictions History

Latest community submissions for CYAD.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
JS Pro	Feb 18, 2020	$10.32 -4.80%	$10.84	X	95.20%	1
Tonia Allen Gould @ToniaAllenGould.140458	Feb 18, 2020	Bearish	$10.84	X	—	0
JS Pro	Jul 1, 2019	$11.25 -6.25%	$12.00	X	93.75%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for CYAD with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT CELYAD SA

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by